Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer
Aachen, Germany, 30 September 2024 – Grünenthal announced today that Jan Adams, M.D., currently Chief Scientific Officer (CSO) and member of the Corporate Executive Board, will assume the role of Chief Commercial Officer (CCO) effective 1 October 2024. Prior to his role as CSO, he was Head of Strategy and Portfolio at Grünenthal.
Jan Adams has over two decades of experience in the pharmaceutical and healthcare industry. Since joining Grünenthal in 2017, he has been key in driving the company's transformational journey. Under his leadership, Grünenthal successfully built a state-of-the-art R&D organisation, redefined its R&D strategy, and built an industry-leading pipeline focused on delivering innovative treatments for acute and chronic pain. Before assuming the role of CSO, he served as Head of Strategy and Portfolio, working at the interface between Strategy, R&D, and Commercial. His role was instrumental in several successful M&A projects and Grünenthal’s entry into the U.S. market. Before joining Grünenthal, he held positions with increasing responsibilities at Takeda, McKinsey & Company, and Novartis. Jan Adams started his career as a resident in cardiology. He is a Medical Doctor by training, married, and has two children.
Jan Adams succeeds Janneke van der Kamp, who will leave Grünenthal to pursue an opportunity outside the company. We are grateful to Janneke for all she has done for Grünenthal and our people and wish her all the very best in her future endeavours.
Keywords
Contacts
Florian Dieckmann, Head of Global Corporate Affairs & Communication
Tel.: +49 241 569-2555
Florian.dieckmann@grunenthal.com
Images
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion.
More information: https://www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Instagram: grunenthal
Subscribe to releases from Grünenthal Group
Subscribe to all the latest releases from Grünenthal Group by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Grünenthal Group
Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia2.6.2025 11:49:26 EEST | Press release
Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability.
Maren Thurow starts as new Head Global Communications at Grünenthal20.5.2025 12:12:34 EEST | Press release
Aachen, Germany, 20th May 2025 - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department since 2021. In her new position, Maren will oversee Grünenthal’s communications operations across all markets and lead the team based at the company’s headquarters in Aachen. She will report directly to CEO Gabriel Baertschi. This appointment comes at a pivotal moment in Grünenthal’s transformation, following the company’s outstanding financial performance in 2024. Since 2017, Grünenthal’s profitability, measured by adjusted EBITDA, has more than tripled, driven by strategic acquisitions and partnerships such as the acquisition of the US company Valinor Pharma and the product Movantik™ in July 2024. Additionally, Grünenthal continues to advance its key R&D programs, including progressing the Glucocorticoid Receptor Modulator (GRM) and Nocicept
Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal25.2.2025 08:41:18 EET | Press release
Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.
Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer9.1.2025 11:54:14 EET | Press release
Aachen, Germany, 09 January 2025 – Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025. Uli Brödl has more than 15 years of industry experience. He joins Grünenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim's Venture Fund Investment Committee. In his most recent role, he oversaw end-to-end clinical development and operations activities across therapeutic areas and worked at the interface of R&D, Commercial, and Market Access functions. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine. Earlier in his career, Uli Brödl led Boehringer Ingelheim's Canadian medical organisation and gained extensive market experience. In parallel, he founded and co-chaired the BI Can
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain7.11.2024 12:44:57 EET | Press release
The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures per year in the U.S.[2] QUTENZA® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug application (sNDA) for a US label extension in 2026, subject to positive data.